New economic strategy team to be charged with developing, guiding growth for Ontario bioscience industry
Health and economic prosperity of Ontarians to flourish with vigorous, commercially viable life-sciences strategy
Major stakeholders in Ontario's life-sciences sector include biotechnology companies, universities and colleges, research institutes, healthcare providers and hospitals, pharmaceutical companies operating in Ontario, and the financial community. The need for an overall strategic vision, embracing all stakeholders, to promote growth and commercial viability of the province's bioscience industry emerged in 2009 from OBIO's regional and online consultations.
The Ontario Ministry of Research and Innovation's recently-announced new commercialization strategy provides one-time special financing of $7 million exclusively for Ontario-based bioscience companies to advance their programs for treating, diagnosing or preventing disease. OBIO's Access to Capital Committee has recommended that this money be urgently deployed to those companies. Ontario spends more than $5 billion a year on drug therapies and devices, most of which are imported.
Gail Garland, president and chief executive officer, OBIO(TM), said: "Bioscience is one industry that can move Ontario beyond its manufacturing roots to a knowledge-based economy that grows jobs, creates economic prosperity and enhances the health of Ontarians. OBEST(TM) will build on the Ontario government's initiatives to facilitate and accelerate the creation of a sustainable and productive bioscience economy."
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.